Why the study?
Are noninvasive biomarkers and transient elastography effective for diagnosing NAFLD/NASH and evaluating fibrosis compared to liver biopsy?
Are noninvasive biomarkers and transient elastography effective for diagnosing NAFLD/NASH and evaluating fibrosis compared to liver biopsy?
Answers are grounded in this paper and cite their sources.
Noninvasive biomarkers and transient elastography offer validated, practical alternatives to liver biopsy for assessing fibrosis and cirrhosis in patients with NAFLD/NASH.
The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and identification of people at risk of disease progression is extremely important. The current gold standard for diagnosing NAFLD/nonalcoholic steatohepatitis (NASH) is by liver biopsy, but it has several limitations. Noninvasive tests via biomarkers and transient elastography to assess NAFLD/NASH are being used in clinical practice. The most validated diagnostic panels include the NAFLD fibrosis score, FIB-4 (Fibrosis-4), and FibroMeter. Transient elastography is very useful in evaluating advanced fibrosis and cirrhosis.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: